European Commission unveils the EU-US Privacy Shield

Life Sciences & Healthcare Update & Alert

Life Sciences & Healthcare Update & Alert

European Commission unveils the EU-US Privacy Shield

The Privacy Shield: how will it impact on the pharmaceutical sector?

UPC court fees and recoverable costs announced

Unified Patent Court Preparatory Committee issues rules on court fees and recovery of costs

Patents Court finds methotrexate patent invalid for lack of inventive step

Patent relating to use of methotrexate in subcutaneous administration in treatment of rheumatoid arthritis found invalid

Patents Court refuses stay of claim for revocation and declaration of non-infringement

The Patents Court applies the IPCom factors and refuses a stay of patent revocation and DNI proceedings

Patents Court guidance on timing of trials

The Patents Court has applied guidance on the timing of patent trials in a pharmaceutical case

Patents Court grants Actavis declarations of non-infringement in pemetrexed dispute

The Patents Court has granted declarations of non-infringement in the UK, France, Italy and Spain to Actavis in relation to its pemetrexed diacid product

The UPC and Unitary Patent: the final countdown

David Rose, European head of IP, and counsel Nina O'Sullivan comment on the state of play of the UPC agreement in an article for IP Magazine.

Government announces proposals to revise Patent Box regime

The Government has announced its proposed changes to the Patent Box which will be published in the Finance Bill 2016

Patents Court rejects Warner-Lambert amendment in pregabalin dispute as an abuse of process

The Patents Court has rejected Warner-Lambert’s conditional application to amend its patent relating to pregabalin.

Patents Court upholds validity of atomoxetine ADHD patent

The Patents Court has upheld the validity of a patent directed to the use of atomoxetine for the treatment of ADHD

European Commission releases sixth report on patent settlements in the pharmaceuticals sector

European Commission report on patent settlements in the pharmaceuticals sector warns of competition law concerns but suggests that intervention is unlikely.